skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of sublingual asenapine in treatment of schizophrenia

Review

(2183) Views  (566) Full article downloads

Authors: Citrome L

Published Date May 2011 Volume 2011:7(1) Pages 325 - 339
DOI: http://dx.doi.org/10.2147/NDT.S16077

Leslie Citrome
New York University School of Medicine, Department of Psychiatry, New York, NY, USA

Abstract: Asenapine tablets are a new option for the treatment of schizophrenia. Sublingual administration is essential because bioavailability if ingested is less than 2%. Efficacy is supported by acute and long-term randomized controlled studies conducted by the manufacturer, with asenapine 5 mg twice daily evidencing superiority over placebo in six-week studies of acute schizophrenia, and flexibly-dosed asenapine (modal dose 10 mg twice daily) superior to placebo in a 26-week maintenance of response study. Tolerability advantages over some second-generation antipsychotics, such as olanzapine, include a relatively favorable weight and metabolic profile, as demonstrated in a 52-week randomized, head-to-head, double-blind clinical trial. Although dose-related extrapyramidal symptoms and akathisia can be present, the frequency of these effects is lower than that for haloperidol and risperidone. Somnolence may also occur, and appears to be somewhat dose-dependent when examining rates of this among patients receiving asenapine for schizophrenia and bipolar disorder. Prolactin elevation can occur, but at a rate lower than that observed for haloperidol or risperidone. Unique to asenapine is the possibility of oral hypoesthesia, occurring in about 5% of participants in the clinical trials. Obstacles to the use of asenapine are the recommendations for twice-daily dosing and the need to avoid food or liquids for 10 minutes after administration, although the bioavailability is only minimally reduced if food or liquids are avoided for only two minutes.

Keywords: antipsychotic, asenapine, clinical trials, schizophrenia




 

Other articles by Dr Leslie Citrome



Readers of this article also read:

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder
Safety and tolerability of antipsychotics: focus on amisulpride
Pharmacotherapy for treatment-resistant schizophrenia
The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder
Risk factors for the development of depression in patients with hepatitis C taking interferon-α
Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder
Ginkgo biloba extract in the treatment of tinnitus: a systematic review
Life satisfaction in patients with chronic pain – relation to pain intensity, disability, and psychological factors
A case of mistaken identity: alcohol withdrawal, schizophrenia, or central pontine myelinolysis?